LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

LLY

998.88

-0.19%↓

JNJ

243.11

-0.23%↓

ABBV

227.62

+0.42%↑

NVS

155.44

-3.77%↓

AZN

192.99

-1.1%↓

Strona główna・Stock List・Kura Oncology Inc

Kura Oncology Inc

Closed

SectorHealthcare

9.2

Buy Sell

Overview

Share price change

24h

Current

Min

8.83

Max

9.38

Key metrics
By Trading Economics
Income	-6.9M -81M
Sales	-3.4M 17M
Profit margin	-467.23
Employees	260
EBITDA	-12M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+201.28% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	62M 817M
Previous open	9.2
Previous close	9.2

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

5.575 / 6.6 Support & Resistance

Kura Oncology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2026, 19:18 UTC

Major Market Movers

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Market Talk

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Market Talk

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Market Talk

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Market Talk

Major News Events

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Major News Events

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Major News Events

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Market Talk

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Earnings

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Earnings

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Earnings

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Earnings

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Earnings

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Acquisitions, Mergers, Takeovers

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Earnings

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Earnings

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Major News Events

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Earnings

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Major News Events

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Market Talk

Major News Events

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Acquisitions, Mergers, Takeovers

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Major News Events

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

201.28% upside

12 Months Forecast

Average 28.29 USD 201.28%

High 40 USD

Low 16 USD

Based on 9 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Kura Oncology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.